NASDAQ: RNAZ - TransCode Therapeutics, Inc.

Rentabilität für sechs Monate: -98.17%
Dividendenrendite: 0.00%
Sektor: Healthcare

Aktionsplan TransCode Therapeutics, Inc.

Erweiterter Zeitplan Einfaches Diagramm
Financial Markets by TradingView

Über das Unternehmen TransCode Therapeutics, Inc.

TransCode Therapeutics, Inc., a ribonucleic acid (RNA) oncology company, focuses on the development and commercialization of drugs and diagnostics for treating and identifying various cancers. Its lead therapeutic candidate is TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in a range of cancers, including breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. The company is also developing TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1; and TTX-siLIN28B, an siRNA-based inhibitor of RNA-binding protein LIN28B.

weitere details
In addition, the company developing TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; TTX-CRISPR, a CRISPR/Cas9-based therapy platform for the repair or elimination of cancer-causing genes inside tumor cells; and TTX-mRNA, an mRNA-based platform for the development of cancer vaccines that activate cytotoxic immune responses against tumor cells. TransCode Therapeutics, Inc. was incorporated in 2016 and is based in Boston, Massachusetts.
Zur Vergleichsliste hinzufügen
Auf die Beobachtungsliste
Zum Portfolio hinzufügen
Preishinweis hinzufügen

IPO date 2021-07-08
ISIN US89357L1052
Industry Biotechnology
Sector Health Care
Валюта usd
Валюта отчета usd
Сайт https://www.transcodetherapeutics.com
Цена ао 0.59
Preisänderung pro Tag: 0% (0.41)
Preisänderung pro Woche: +5.67% (0.388)
Preisänderung pro Monat: -47.29% (0.7778)
Preisänderung über 3 Monate: -87.8% (3.36)
Preisänderung über sechs Monate: -98.17% (22.407)
Preisänderung pro Jahr: -18.81% (0.505)
Preisänderung über 3 Jahre: -85.61% (2.85)
Preisänderung seit Jahresbeginn: -89.54% (3.92)
Alle Parameter

Unterschätzung

Name Bedeutung Grad
P/S 0 0
P/BV 0.8291 9
P/E 0 0
EV/EBITDA 0.0506 10
Gesamt: 4.88

Effizienz

Name Bedeutung Grad
ROA, % -358.75 0
ROE, % -1130.3 0
Gesamt: 0

Dividenden

Name Bedeutung Grad
Div yield, % 0 0
DSI 0 0
Gesamt: 0

Pflicht

Name Bedeutung Grad
Debt/EBITDA -0.0238 10
Gesamt: 9.2

Wachstumsimpuls

Name Bedeutung Grad
Rentabilität Revenue, % 0 0
Rentabilität Ebitda, % 3832.92 10
Rentabilität EPS, % 88301.02 10
Gesamt: 8
Weitere Details

Institutionen Volumen Aktie, %
Sabby Management, LLC 250309 1
UBS Group AG 146530 0.58
Tang Capital Management, LLC 84010 0.33
Private Capital Management LLC 80704 0.32
Virtu Financial LLC 31347 0.12
HRT Financial LP 16358 0.07
Two Sigma Investments, LP 16153 0.06
Warberg Asset Management LLC 10000 0.04
Tower Research Capital LLC (TRC) 5340 0.02
Royal Bank of Canada 22 0



Aufsicht Berufsbezeichnung Zahlung Geburtsjahr
Mr. Thomas A. Fitzgerald M.B.A. Interim CEO, CFO, President, VP of Administration & Director 358.14k 1952 (73 Jahr)
Dr. Zdravka Medarova Ph.D. Co-Founder & Chief Scientific Officer N/A 1975 (50 Jahre)
Dr. Anna Moore Ph.D. Co-Founder, Scientific Advisor & Member of Scientific Advisory Board N/A 1962 (63 Jahr)
Ms. Susan Duggan M.B.A., R.N. Senior Vice President of Operations N/A
Dr. Philippe P. Calais Ph.D., Pharm., Pharm.D. Executive Chairman of the Board 102.5k 1959 (66 Jahre)
Dr. Daniel R. Vlock M.D. Chief Medical Officer 1952 (73 Jahr)

Adresse: United States, Boston. MA, 6 Liberty Square - in Google Maps öffnen, Öffnen Sie Yandex-Karten
Webseite: https://www.transcodetherapeutics.com